Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Unresectable or Metastatic Hepatocellular Carcinoma
NCT00142428Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2005
- Primary completion
- Oct 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in hepatocellular carcinoma (HCC), sponsored by Massachusetts General Hospital. Primary endpoint: Progression Free Survival at 2 years. Started Jan 2005; status: completed.
02
Drugs
KL-140
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00142428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142428.